Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antihistamines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Antihistamines. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-022784-35 Sponsor Protocol Number: Q4883g Start Date*: 2011-08-08
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATME...
    Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021247 Idiopathic urticaria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007657-31 Sponsor Protocol Number: MIARCU 01/2008 Start Date*: 2008-06-23
    Sponsor Name:Charité-University Berlin
    Full Title: Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria
    Medical condition: Urticaria characterized by mast cell and histamine-dependent wheal and flair type-skin responses associated with severe pruritus. The disease is very common and not always easy to treat. Mainstay t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002350-63 Sponsor Protocol Number: SL300/2004/002/D Start Date*: 2004-11-19
    Sponsor Name:Stallergenes GmbH & Co.KG
    Full Title: Efficacy and Safety of Sublingual Immunotherapy with Ultra-Rush Titration in Children with Allergic Rhinoconjunctivitis to Tree Pollen, a Multicentre DBPC Trial
    Medical condition: Allergic rhinitis against birch pollen
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001591-11 Sponsor Protocol Number: 3.4.11.049 Start Date*: 2012-12-21
    Sponsor Name:Erasmus MC
    Full Title: Symptomatic treatment of pollen related allergic rhinoconjunctivitis and the relation with asthma with children in the General practice
    Medical condition: Allergic Rhinitis Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004624-35 Sponsor Protocol Number: GS39684 Start Date*: 2017-05-10
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU)
    Medical condition: Chronic spontaneous urticaria (CSU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000149-42 Sponsor Protocol Number: SYN008-002 Start Date*: 2021-08-16
    Sponsor Name:Synermore Biologics Co., Ltd
    Full Title: A Phase 3, Randomized, Double-blind, Parallel group, Active Controlled Study to Compare the Efficacy and Safety of SYN008 to Xolair® in Adult Patients with Chronic Spontaneous Urticaria and Inadequ...
    Medical condition: Chronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002273-22 Sponsor Protocol Number: 1/2013 Start Date*: 2013-07-24
    Sponsor Name:Azienda Ospedaliera L. Sacco - Clinica Pediatrica
    Full Title: Efficacy of Pidotimod in the prevention of respiratory infections in healthy children: a randomized, double blind, placebo controlled study.
    Medical condition: respiratory infections in children.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002339-24 Sponsor Protocol Number: NA Start Date*: 2012-05-25
    Sponsor Name:Barts and the London NHS Trust
    Full Title: Open label, single-centre study to evaluate the efficacy of the bradykinin (BK) B2 receptor antagonist, Icatibant, in the relief of symptoms resulting from moderate to severe angioedema unresponsiv...
    Medical condition: Idiopathic Angioedema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020063-21 Sponsor Protocol Number: ILUVIT1 Start Date*: 2010-06-15
    Sponsor Name:Charité-Universitätsmedizin
    Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”
    Medical condition: Urticarial vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048820 Urticarial vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003828-23 Sponsor Protocol Number: ML39310 Start Date*: 2017-04-11
    Sponsor Name:Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy
    Full Title: A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)
    Medical condition: Schnitzler’s syndrome (SchS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023861-23 Sponsor Protocol Number: EPU P61 Start Date*: 2011-01-31
    Sponsor Name:Maastricht University
    Full Title: The effect of P-glycoprotein transport inhibition on brainmechanisms of sedation and cognitive impairment following antihistamines in healthy volunteers
    Medical condition: To assess the effects of inhibition of the P-glycoproteine transporter (by verapamil 120 mg) on cetirizine 15 mg in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001601-85 Sponsor Protocol Number: UKM10_0037 Start Date*: 2014-02-14
    Sponsor Name:University Hospital Münster
    Full Title: Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial
    Medical condition: Patients with generalized chronic pruritus (> 6 weeks duration) and showing prurigo nodularis refractory to pretreatment with antihistamines (normal dosage, four weeks)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10037084 Prurigo nodularis LLT
    17.0 100000004858 10018123 Generalized pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003411-19 Sponsor Protocol Number: CPU-003 Start Date*: 2017-11-09
    Sponsor Name:Fakultní nemocnice u sv. Anny v Brně
    Full Title: Compatibility of clopidogrel prepared for administration through nasogastric tube with enteral nutrition (CPU-003)
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005127-27 Sponsor Protocol Number: CIGE025ENL01T Start Date*: 2015-05-29
    Sponsor Name:UMC Utrecht
    Full Title: Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria
    Medical condition: Chronic spontaneous urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004222-93 Sponsor Protocol Number: GPE 02 Start Date*: 2006-11-28
    Sponsor Name:Curalogic A/S
    Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated Grass (Phleum pratense) Pollen Extract (MGPE) in Subjects with Grass Pollen Allergy in a Randomized, Double-Blind, Placebo-Controlled...
    Medical condition: Treatment of seasonal allergic rhinitis to grass pollen.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004538-18 Sponsor Protocol Number: RPE 07 Start Date*: 2007-12-19
    Sponsor Name:Curalogic A/S
    Full Title: A randomized doble-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extract
    Medical condition: Patients with ragweed pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000513-29 Sponsor Protocol Number: CLU-2008-001 Start Date*: 2008-09-30
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact...
    Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006335-12 Sponsor Protocol Number: Ecorhino Start Date*: 2008-11-18
    Sponsor Name:Prof. Dr. med. Margitta Worm
    Full Title: Explorative analysis of the immunmodulatory capacities of apathogenic Escherichia coli Nissle 1917 in patients with rhinoconjunctivitis due to grass pollen allergy.
    Medical condition: Due to the worldwide increasing prevalence of allergic rhinoconjunctivitis (AR), new therapeutical strategies are needed. The symptomatic treatment with topical and systemic antihistamines and cort...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004961-38 Sponsor Protocol Number: EXP-2177 Start Date*: 2021-03-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria
    Medical condition: cholinergic urticaria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10008675 Cholinergic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA